Cullinan Therapeutics, Inc. — Form 8-K
Filed November 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Cullinan's BCMAxCD3 T cell engager velinotamig (licensed from Genrix Bio) treated 12 patients across three dose cohorts as of September 8, 2026. Among 9 evaluable patients with ≥4 weeks follow-up, 8 of 9 achieved ≥4-point SLEDAI-2K reduction; 4 of 7 with baseline proteinuria >500 mg/24h achieved complete renal response (<500 mg/24h) within 24 weeks. Safety profile was favorable: zero dose-limiting toxicities, zero ICANS, no Grade 3+ CRS (only Grade 1–2 in 2 patients, resolved with standard management).
Why this rating
Early Phase 1b/2a data in high-unmet SLE nephritis on lead asset; strong efficacy signals (89% SLEDAI response, 57% complete renal response) and clean safety support pipeline value. For $442M market-cap stage-company, positive clinical validation of core mechanism is material but still early; de-risking ahead of Phase 2 expansion.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $11.32 | +10 min · unknown $10.96 ▼ 3.18% | +30 min · unknown $11.31 ▼ 0.09% | +1 hr · unknown $11.69 ▲ 3.22% | +4 hrs · unknown $12.20 ▲ 7.77% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.